Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
China Biologic Products Holdings, Inc. (CBPO)
|
Add to portfolio |
|
|
|
| Price: |
$118.28
| | Metrics |
| OS: |
38.5
|
M
| |
6
|
% ROE
|
| Market cap: |
$4.55
|
B
| |
9
|
% ROIC
|
|
Net cash:
|
$924
|
M
| |
$24.03
|
per share
|
|
EV:
|
$3.62
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$160
|
M
| |
22.7
|
x EV/EBITDA
|
|
EBIT
|
$146
|
M
| |
24.9
|
x EV/EBIT
|
| EPS |
$4.06
| |
29.1
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 503.7 | 466.9 | 370.4 | 341.2 | 296.5 | 243.3 | 203.4 | 184.8 |
| Revenue growth | 7.9% | 26.0% | 8.6% | 15.1% | 21.9% | 19.6% | 10.0% | 20.7% |
| Cost of goods sold | 174.7 | 146.8 | 125.5 | 124.0 | 106.5 | 80.0 | 65.5 | 58.8 |
| Gross profit | 329.1 | 320.1 | 244.9 | 217.1 | 190.0 | 163.2 | 137.9 | 126.0 |
| Gross margin | 65.3% | 68.6% | 66.1% | 63.6% | 64.1% | 67.1% | 67.8% | 68.2% |
| Sales and marketing | 80.3 | 95.6 | 34.8 | 11.7 | 10.0 | 10.7 | 10.6 | 14.4 |
| Research and development | 11.7 | 9.5 | 6.5 | 7.0 | 6.0 | 4.2 | 4.2 | 3.0 |
| General and administrative | 73.4 | 68.8 | 67.7 | 54.5 | 41.4 | 32.1 | 36.1 | 34.0 |
| EBITA | 173.4 | 157.3 | 139.9 | 147.0 | 132.1 | 120.6 | 90.5 | 80.2 |
| EBITA margin | 34.4% | 33.7% | 37.8% | 43.1% | 44.6% | 49.6% | 44.5% | 43.4% |
| Amortization of intangibles | 8.1 | 8.7 | 0.5 | 0.6 | 0.9 | 0.8 | 1.4 | 3.1 |
| EBIT | 165.2 | 148.5 | 139.4 | 146.4 | 131.3 | 119.8 | 89.1 | 77.2 |
| EBIT margin | 32.8% | 31.8% | 37.6% | 42.9% | 44.3% | 49.3% | 43.8% | 41.7% |
| Pre-tax income | 191.5 | 166.0 | 146.4 | 153.9 | 135.1 | 122.8 | 92.4 | 81.1 |
| Income taxes | 28.1 | 18.0 | 64.2 | 25.1 | 21.0 | 26.6 | 15.5 | 15.2 |
| Tax rate | 14.7% | 10.9% | 43.8% | 16.3% | 15.5% | 21.7% | 16.8% | 18.7% |
| Net income | 138.8 | 128.1 | 67.9 | 104.8 | 89.0 | 70.9 | 54.6 | 45.2 |
| Net margin | 27.6% | 27.4% | 18.3% | 30.7% | 30.0% | 29.2% | 26.9% | 24.5% |
| |
| Diluted EPS | $3.57 | $3.61 | $2.46 | $3.85 | $3.35 | $2.76 | $1.98 | $1.68 |
| Shares outstanding (diluted) | 38.9 | 35.4 | 27.6 | 27.2 | 26.6 | 25.7 | 27.6 | 26.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|